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ABSTRACT
Objective We describe the occurrence and course
of anterior pituitary dysfunction (PD) after aneurysmal
subarachnoid haemorrhage (SAH), and identify clinical
determinants for PD in patients with recent SAH.
Methods We prospectively collected demographic and
clinical parameters of consecutive survivors of SAH and
measured fasting state endocrine function at baseline,
6 and 14 months. We included dynamic tests for
growth-hormone function. We used logistic regression
analysis to compare demographic and clinical
characteristics of patients with SAH with and without PD.
Results 84 patients with a mean age of 55.8 (±11.9)
were included. Thirty-three patients (39%) had PD in one
or more axes at baseline, 22 (26%) after 6 months and
6 (7%) after 14 months. Gonadotropin deﬁciency in 29
(34%) patients and growth hormone deﬁciency (GHD) in
26 (31%) patients were the most common deﬁciencies.
PD persisted until 14 months in 6 (8%) patients: GHD in
5 (6%) patients and gonadotropin deﬁciency in 4 (5%).
Occurrence of a SAH-related complication was associated
with PD at baseline (OR 2.6, CI 2.2 to 3.0).
Hydrocephalus was an independent predictor of PD
6 months after SAH (OR 3.3 CI 2.7 to 3.8). PD was
associated with a lower score on health-related quality of
life at baseline (p=0.06), but not at 6 and 14 months.
Conclusions Almost 40% of SAH survivors have PD.
In a small but substantial proportion of patients GHD or
gonadotropin deﬁciency persists over time. Hydrocephalus
is independently associated with PD 6 months after SAH.
Trial registration number NTR 2085.
INTRODUCTION
Patients with aneurysmal subarachnoid haemor-
rhage (SAH) with a seemingly good clinical
outcome often present with fatigue and experience
high levels of psychosocial stress.1 These symptoms
may interfere with daily activities and social partici-
pation, reducing quality of life in relatively young
patients with SAH.2 3 They resemble the symptoms
reported by patients with anterior pituitary dys-
function (PD).4 PD has been reported in 0 to 55%
of SAH survivors.5–9 The most consistent ﬁnding is
a high proportion of patients with growth
hormone deﬁciency (GHD).9–11 However, reported
incidences vary between studies and the course of
PD after SAH is not well known. PD was found to
be transient,12 but seemed long-lasting in other
studies.13 Increased age, hydrocephalus and vaso-
spasm have been identiﬁed as possible predictors
for PD after SAH,7 9 however, others could not
conﬁrm this.6 13
The conﬂicting results may be explained by dif-
ferences in methodology and study population as
well as time since onset of SAH.5 7 To evaluate the
growth hormone (GH) and adrenocorticotropic
releasing hormone (ACTH), most of the studies
conducted dynamic tests,9 11 but some did not.6 7
In some studies, patients were selected on the basis
of symptoms of fatigue14 or on location of the
aneurysm.15
In the Hypopituitarism In Patients with
Subarachnoid haemorrhage (HIPS) study. We pro-
spectively assessed the frequency and course of PD
over time, using standardised laboratory tests to
evaluate neuroendocrine function in a Dutch
cohort of aneurysmal SAH survivors. In addition,
we searched for clinical risk factors for hypopituit-
arism after SAH.
METHODS
Study design
The HIPS study was a prospective single-centre
observational cohort study. It was registered and
approved by the IRB at Erasmus MC University
Medical Center, and registered in the Dutch trial
registry (NTR 2085). All patients gave written
informed consent. The inclusion and exclusion of
participants are described in detail elsewhere.16 In
short, consecutive patients who survived the acute
phase of SAH were asked to participate.
DATA COLLECTION
We prospectively collected baseline characteristics
on all patients, including age, medical history,
medication use and cardiovascular risk factors. At
admission we noted the following neurological
parameters: World Federation of Neurological
Surgeons (WFNS) grading scale for patients with
SAH, Glasgow Coma Scale (GCS), radiological
severity of SAH,17 aneurysm location and type of
intervention.
We recorded SAH-related complications consist-
ing of hydrocephalus (HC), rebleeding, vasospasm,
delayed cerebral ischaemia (DCI), intracerebral
haematoma (ICH), hypertension (HT) and hypona-
traemia. Patients with symptomatic HC were all
Open Access
Scan to access more
free content
Cerebrovascular disease
Khajeh L, et al. J Neurol Neurosurg Psychiatry 2015;86:905–910. doi:10.1136/jnnp-2014-307897 905
treated either by external ventricular drainage or external
lumbar drainage prior to endocrine evaluation.
CLINICAL DEFINITIONS AND OUTCOME MEASURES
SAH diagnosis was conﬁrmed by CT of the brain and in cases
with negative CT, by lumbar puncture. Presence and location of
the aneurysm was determined by CT angiography and/or a
digital subtraction angiography.
The methods of endocrine testing and deﬁnitions of PD have
been described in detail elsewhere.16 In short, at baseline and
6 month after SAH endocrine tests were performed and
reviewed by an endocrinologist. Endocrine tests included
ghrelin test at baseline and GHRH-arginine test 6 months after
SAH, in fasting patients. Fourteen months after SAH, all
patients were scheduled for basal hormonal testing. In addition,
patients with GHD were scheduled for GHRH-arginine test. All
basal serum samples were taken during fasting before 9:00.
ACTH insufﬁciency was considered if basal cortisol level was
<110 nmol/L or if cortisol peak during ghrelin test was
<450 nmol/L.18 Criteria for thyroid stimulating hormone
(TSH) deﬁciency were low serum fT4 level (<11 pmol/L) com-
bined with an inadequate TSH levels. Gonadotropin insufﬁ-
ciency was deﬁned when testosterone was ≤10 nmol/L or by
inadequate LH levels. In postmenopausal women, LH was
regarded as derogatory when below 15 U/L and/or when
follicle-stimulating hormone (FSH) was below 35 U/L. In
younger women dependent on the stage of cycle and LH, and
FSH and E2, gonadal status was assessed. In case oral contracep-
tives were used, gonadal function could not be assessed. We
deﬁned anterior PD as when any of the pituitary axis was con-
sidered abnormal.
Health-related quality of life (HRQOL) was assessed using
question on life satisfaction modules (QLSM-H), a questionnaire
that has been developed to evaluate HRQOL in patients with
hypopituitarism, among whom are patients with adult GHD.19
STATISTICAL ANALYSIS
Descriptive statistics were used to describe the prevalence of
hypopituitarism after SAH. Cardiovascular risk factors prior to
SAH, severity of SAH (WFNS, GCS), the presence of hydro-
cephalus, hypertension, delayed cerebral ischaemia and rebleed
were considered as predictors for PD. Independent sample
t tests were used for continuous variables and Pearson’s χ2 test
for categorical variables. Associations of risk factors with PD
were expressed as ORs with 95% CI. Those with a signiﬁcance
level of p<0.05 were entered in a multiple logistic regression
model using forward selection to determine the independent
predictive value of the parameters. We adjusted for potential
confounders such as age and sex. All statistical analyses were
performed with SPSS V.20.0 (SPSS Inc, Chicago, Illinois, USA).
RESULTS
Of the 198 patients with SAH who were admitted to the ICU, 48
(24%) died, 38 (19%) refused to participate, 20 (10%) were dis-
charged to other hospitals before inclusion and 8 were excluded
for various other reasons. In total, 84 patients were included in
the study (ﬁgure 1). There were no signiﬁcant differences in age
(p=0.18), sex (p=0.24), GCS on admission (p=0.81) and dur-
ation of hospital stay (p=0.53) between the included and
excluded patients who survived the acute phase.
The baseline and clinical characteristics are shown in tables 1
and 2. Twenty-eight men (33%) and 56 (67%) women were
included. Mean age was 55.7 (±11.9) years. All 84 patients
were tested for PD at baseline, 72 (86%) at 6 months and 68
(81%) patients 14 months after SAH. Fifty-nine patients (71%)
also had a ghrelin test at baseline and 54 (65%) patients a
GHRH-arginine test 6 months after SAH. For the ﬁrst 10
Figure 1 Flowchart of patient
inclusion.
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patients, ghrelin was not available due to logistic problems.
Fifteen patients refused dynamic testing.
During follow-up, ﬁve patients died of cardiovascular disease
consisting of myocardial infarction and cardiac dysrhythmia. In
addition, cerebral infarction occurred in 3 (4%) and myocardial
infarction occurred in two patients (2%). None of these patients
had PD prior to the cardiovascular event. One of the patients
with GHD developed prostate carcinoma.
Frequency and course of hypopituitarism
Mean time to baseline evaluation was 32 days. Twenty-nine
(34%) patients had gonadotropin insufﬁciency, 26 (31%) pos-
sible GHD, 1 (1%) TSH deﬁciency and 1 (1%) ACTH insufﬁ-
ciency. All female patients (n=19) with gonadotropin deﬁciency
were postmenopausal (mean age 58±10 years). Thirty-seven
(44%) patients were deﬁcient on one or more of the endocrine
axes at initial evaluation. In 26 (32%) patients only a single axis
was deﬁcient and in 11 (13%) two axes were deﬁcient. GHD
combined with gonadotropin deﬁciency was present in all but
one patient who had combined TSH and gonadotropin
deﬁciency.
The frequency and number of affected axes are depicted in
table 3. Twenty-two (26.2%) patients had PD 6 months after
SAH, which consisted of gonadotropin insufﬁciency (20%),
GHD (9.5%) and TSH deﬁciency (1.2%). All female patients
with gonadotropin deﬁciency were postmenopausal. Four
patients had two axes affected consisting of GHD and gonado-
tropin deﬁciency in all cases.
Of the 8 patients with GHD at 6 months, two refused retest-
ing at 14 months. In one patient, GH function had recovered,
testing negative for GHRH-arginine test. PD was present in 6
(7.2%) patients. Five male patients (84%) had GHD of whom 3
(60%) also had gonadotropin deﬁciency. One postmenopausal
female patient had isolated gonadotropin deﬁciency. In all other
patients, pituitary functions were normal.
Clinical determinants for PD
Table 4 shows the clinical and radiological characteristics of the
SAH patients in relation to the presence or absence of endocrine
dysfunction at baseline and after 6 months’ follow-up.
In univariable analysis, hydrocephalus (OR 3.3, 95% CI 1.2
to 8.9), GCS <13 on admission (OR 2.79, 95% CI 1.0 to 8.9),
WFNS >2 on admission (OR 2.9, 95% CI 1.1 to 8.3) and
hypertension after SAH (OR3.2, 95% CI 1.2 to 8.7) were asso-
ciated with the occurrence of PD 6 months after SAH. In a mul-
tivariable analysis adjusting for age, gender and hypertension,
patients with any SAH-related complication had a signiﬁcantly
higher chance of having PD at baseline (OR 2.6, 95% CI 2.2 to
3.0). Hydrocephalus remained independently associated with
hypopituitarism at 6 months (OR 3.3, 95% CI 2.7 to 3.8).
GHD at 6 month after SAH was associated with male gender
(OR 17.8, 95% CI 2.0 to 58.9). This association persisted after
retesting 14 months after SAH. We found no association
between aneurysm location and pituitary function. Other non-
signiﬁcant ﬁndings are added in online supplementary table S4.
We found a trend (p=0.06) for lower score on the QLSM-H
at baseline in patients with PD compared with patients without
PD, but this trend was not present any more after 6 or
14 months.
DISCUSSION
In this prospective observational study, 39% of survivors of
aneurysmal SAH were deﬁcient in one or more pituitary axes at
Table 1 Baseline characteristics of included patients
Characteristics N 84
Age (mean (SD)) 55.7 (11.9)
Male 28 (33%)
History of hypertension 18 (21%)
Body mass index (mean, (SD)) 25.3 (3.7)
History of smoking 52 (62%)
History of hypercholesterolaemia 15 (18%)
History of diabetes mellitus* 4 (5%)
*All patients had diabetes mellitus type II.
Table 2 Clinical characteristics of included patients
Clinical characteristics N 84 (%)
GCS on admission
13–15 66 (79)
9–12 11 (13)
3–8 7 (8)
WFNS on admission
Grade I 38 (45)
Grade II 25 (30)
Grade III 3 (4)
Grade IV 11 (13)
Grade V 7 (8)
Aneurysm location
Anterior Circulation 49 (58)
Posterior Circulation 35 (42)
Intervention
Coiling 66 (79)
Clipping 17 (20)
None 1 (1)
Complications
None 43 (51)
Hydrocephalus 31 (37)
Rebleed 2 (2)
Delayed cerebral ischaemia 8 (10)
Intraparenchymal haematoma 15 (18)
Intraventricular haematoma 56 (67)
Vasospasm 7 (8)
GCS, Glasgow Coma Scale.
Table 3 Occurrence of pituitary deficiency
Hormone
deficiencies
Baseline
6 months’
follow-up
14 months’
follow-up
N (%)
m/f
ratio N (%)
m/f
ratio N (%)
m/f
ratio
Any deficiency 37 (44%) 10/27 22 (26%) 10/12 6 (7%) 5/1
GH deficiency 26 (31%) 7/19 8 (10%) 7/1* 5 (6%) 5/0*
Gonadotropin
deficiency
29 (34%) 10/19 17 (20%) 5/12 4 (5%) 3/1
ACTH deficiency 1 (1%) 0/1 – – – –
TSH deficiency 1 (1%) 0/1 – – – –
Number (%) of deficient pituitary axes and male/female ratio of deficient patients at
baseline, 6 and 14 months after SAH.
*p<0.001; OR:17.8 after 6 months.
ACTH, adrenocorticotropic releasing hormone; GH, growth hormone; SAH,
subarachnoid haemorrhage; TSH, thyroid stimulating hormone.
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baseline. PD did not occur during follow-up in patients with
normal pituitary function at baseline. PD persisted for 6 months
in 26% of patients and for at least 14 months in 7%.
Gonadotropin and GH were most often affected. Patients were
prone to have PD in the early stage after SAH if they had devel-
oped any of the well-known complications related to SAH.
Hydrocephalus was associated with PD 6 months after SAH and
male sex was associated with persistent GHD.
The prevalence of patients with hypopituitarism after SAH
exceeds the prevalence in the normal population.20 Together
with the decrease in PD over time, and the association of PD to
SAH-related complications and the severity of SAH symptoms,
this supports the evidence for a causal relation between SAH
and hypopituitarism.
Gonadotropin and/or GHD occurred more frequently than
ACTH or TSH deﬁciency, which is in accordance with other
studies.5 9 21 Since it is the anterior lobe of the pituitary gland
that contains predominantly thyrotrope, somatotrope and gona-
dotrope cells,22 this observation suggests that this lobe is more
vulnerable to damage secondary to SAH. This might be due to
differences in the position of the pituitary parts in the skull or
to differences in blood supply. Blood is supplied to the anterior
lobe through long pituitary portal vessels that transcend from
above the diaphragma sellae, whereas the blood supply to the
remaining part of the pituitary gland is derived form middle
and inferior pituitary arteries.4
In the majority of patients with PD, pituitary function recov-
ered during follow-up, while in a small proportion of patients
PD persisted. This has been described in similar studies,9 12 and
is in accordance with studies that found only low numbers of
patients with PD long after SAH.21 23 Recent ﬁndings suggest
that the adult pituitary gland is capable of regeneration after
injury,24 which might explain the recovery of pituitary function
in our patients. The low proportion of patients with persistent
PD described in our and other recent studies differs strongly
from that of the older studies.5 6 11 This is probably explained
by methodological differences between the studies. In some
studies the tests used for detecting PD were not validated.11 In
Table 4 Potential risk factors for PD at baseline and 6 months after SAH
Clinical characteristics
Baseline 6 months’ follow-up
With PD
N=37
Without PD
N=47
With PD
N=22
Without PD
N=62
Age; mean (SD) 57.5 (11.9) 54.3 (11.8) 52.9 (12.0) 56.7 (11.8)
Male 10 (27%) 18 (38%) 10 (45%) 18 (29%)
Days in hospital; mean (SD) 18.4 (8.1) 18.0 (10.9) 19.7 (9.1) 17.7 (9.9)
History of smoking 23 (62%) 29 (62%) 14 (64%) 38 (61%)
History of hypertension 11 (30%) 7 (15%) 6 (27%) 12 (19%)
History of DM 0 4 (9%) 0 4 (6%)
History of hypercholesterolaemia 8 (22%) 7 (15%) 2 (9%) 13 (21%)
BMI; mean (SD) 25.5 (4.1) 25.1 (3.4) 25.2 (3.6) 25.3 (3.8)
GCS on admission *
13–15 27 (73%) 39 (83%) 14 (64%) 52 (84%)
9–12 5 (13.5%) 6 (13%) 4 (18%) 7 (11%)
3–8 5 (13.5%) 2 (4%) 4 (18%) 3 (5%)
WFNS on admission *
Grade I 14 (38%) 24 (51%) 8 (36%) 31 (50%)
Grade II 11 (30%) 14 (30%) 5 (23%) 20 (32%)
Grade III 2 (5%) 1 (2%) 1 (5%) 2 (3%)
Grade IV 5 (13.5%) 6 (13%) 4 (18%) 7 (11%)
Grade V 5 (13.5%) 2 (4%) 4 (18%) 3 (5%)
Location of aneurysm
Anterior circulation 17 (46%) 31 (66%) 12 (55%) 37 (60%)
Posterior circulation 20 (54%) 16 (34%) 10 (45%) 25 (40%)
SAH treatment
Coiling 30 (81%) 36 (77%) 19 (86%) 47 (76%)
Clipping 6 (19%) 11 (23%) 2 (9%) 15 (24%)
Complications ‡
Any 23 (62%) 18 (38%) 14 (64%) 27 (44%)
Hydrocephalus 18 (49%) 13 (28%) 13 (59%)† 18 (29%)
Delayed Cerebral Ischaemia 7 (19%) 7 (15%) 3 (14%) 11 (18%)
Rebleed 1 (3%) 1 (2%) 0 2 (3%)
ICH 5 (13.5%) 10 (21%) 3 (14%) 12 (19%)
IVH 26 (70%) 30 (64%) 13 (59%) 43 (69%)
Hypertension after SAH 20 (54%) 29 (62%) 14 (64%)* 22 (35%)
*p<0.05.
†OR 3.3 (95% CI 2.7 to 3.8).
‡OR 2.6 (95% CI 2.2 to 3.0).
BMI, body mass index; GCS, Glasgow Coma Scale; ICH, intraparenchymal haematoma; IVH, intraventricular haematoma; PD, pituitary dysfunction; SAH, subarachnoid haemorrhage.
WFNS, World Federation of Neurological Surgeons grading scale for patients with SAH.
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other studies, GHRH-arginine test outcomes were not adjusted
for body mass index (BMI),10 13 and because obesity is a true
confounder of the GHRH-arginine test and other dynamic tests,
this strongly reduces the accuracy of the GH response.18 25 26 In
our study, we used two different dynamic tests to establish
GHD, and BMI related cut-off points were used in accordance
with recent recommendations.21 27 Furthermore, we retested
patients with GHD 14 months after SAH to explore whether
GHD was a permanent or a transient phenomenon.
We found an independent association between hydrocephalus
and persistent PD. Few studies have evaluated possible clinical
determinants of hypopituitarism after SAH. Vasospasm and
hydrocephalus were identiﬁed as risk factors for PD in one
retrospective study with a non-consecutive series of patients
without using dynamic tests.7 Other studies reported an associ-
ation between female gender and corticotrophin deﬁciency11
and between older age and GHD in the acute phase after SAH.9
We observed that PD or GHD was predominantly present in
men, which is in line with a recent study.21 We did not ﬁnd an
association of PD and the location of the aneurysm, which is in
line with the results of a recent published study.15 However,
numbers were small.
Hydrocephalus might play an important role in altering the
pituitary function by increasing the intracranial pressure and
altering anatomic conﬁguration, which might lead to damage of
the hypothalamic-pituitary complex. We also observed that
severity of SAH, expressed as worse GCS and worse
WFNS-scores, were associated with hypopituitarism in univari-
able analysis. Even though these determinants were not signiﬁ-
cant in multivariable analysis (possibly due to the low number
of cases with PD in our study), this adds to the evidence that
the pituitary gland is damaged by SAH and its complications.
Not many studies describe the association of long-term symp-
toms as HRQOL with the occurrence of PD. In our study, a
strong overall association was not present.
Whether patients with SAH should be screened for PD is
under debate, because clinical signiﬁcance is not clear. However,
there are various other reasons besides the possible association
with long-term symptoms to consider early neuroendocrine
evaluation of patients with SAH. Adrenal insufﬁciency might be
life-threatening in the early stressful period after SAH and
recent ﬁndings suggest that early PD has a negative effect on
outcome after SAH.28 Although we found adrenal insufﬁciency
in only 1 (2%) patient, in other studies the proportion of
patients with adrenal insufﬁciency was higher, up to 40%.9 11
Early screening for PD might be beneﬁcial in the long-term
after SAH. Symptoms of GHD consist of fatigue, low energy
level, and decline in cognitive function such as memory and
planning,4 symptoms often found after SAH.3 29 These symp-
toms might hamper the rehabilitation process. A few studies
show a decrease in performance functions and life satisfaction in
patients with PD after SAH,30 but others do not support
this.21 23
Our study has several limitations. Not all of our patients had
a dynamic test to evaluate GHD. This may have led to an under-
estimation of the number of patients with PD. Furthermore,
two patients with GHD refused re-evaluation after 14 months.
The follow-up period was limited and the possibility of recovery
of pituitary function beyond this 14-month period cannot be
ruled out.
Another limitation is patient selection. Twenty patients were
transferred to another hospital for treatment before inclusion
was fulﬁlled. Furthermore, we have chosen to include patients
who survived the acute phase of SAH. Our selection was based
on the idea that we wanted to investigate the course of hypo-
pituitarism in the long-term survivors. Our results cannot, there-
fore, be generalised to all patients with acute SAH.
In conclusion, PD is an actual complication in SAH survivors.
Hydrocephalus after SAH is an independent clinical predictor
of long-term hypopituitarism after SAH.
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